Aion Therapeutic (XCNQ:AION) FCF Margin % : -42.53% (As of Oct. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aion Therapeutic's Free Cash Flow for the three months ended in Oct. 2024 was C$-0.15 Mil. Aion Therapeutic's Revenue for the three months ended in Oct. 2024 was C$0.35 Mil. Therefore, Aion Therapeutic's FCF Margin % for the quarter that ended in Oct. 2024 was -42.53%.

As of today, Aion Therapeutic's current FCF Yield % is -16.88%.

The historical rank and industry rank for Aion Therapeutic's FCF Margin % or its related term are showing as below:

XCNQ:AION' s FCF Margin % Range Over the Past 10 Years
Min: -230.25 Med: -230.25 Max: -109.48
Current: -109.48

During the past 8 years, the highest FCF Margin % of Aion Therapeutic was -109.48%. The lowest was -230.25%. And the median was -230.25%.

XCNQ:AION's FCF Margin % is ranked worse than
91.11% of 990 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs XCNQ:AION: -109.48

Aion Therapeutic FCF Margin % Historical Data

The historical data trend for Aion Therapeutic's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic FCF Margin % Chart

Aion Therapeutic Annual Data

Trend

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

FCF Margin %

Get a 7-Day Free Trial

-230.25

Aion Therapeutic Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
FCF Margin %	Get a 7-Day Free Trial															-	109.46	-557.93	-125.29	-42.53

Competitive Comparison of Aion Therapeutic's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's FCF Margin % falls into.

Aion Therapeutic FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aion Therapeutic's FCF Margin for the fiscal year that ended in Apr. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Apr. 2024 )	/	Revenue (A: Apr. 2024 )
	=	-0.845	/	0.367
	=	-230.25 %

Aion Therapeutic's FCF Margin for the quarter that ended in Oct. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Oct. 2024 )	/	Revenue (Q: Oct. 2024 )
	=	-0.148	/	0.348
	=	-42.53 %

Aion Therapeutic FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aion Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ANTCF:USA

Address

700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8

Website

https://www.aiontherapeutic.com

Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.

Executives

Ismail Abdul Fattah	Director or Senior Officer of 10% Security Holder
Douglas Craig Wilson	Director or Senior Officer of 10% Security Holder
John Graham Simmonds	Director, Senior Officer

Aion Therapeutic Headlines

No Headlines